Myocardial Protection During Cardiotoxic Chemotherapy
Key result
Targeted cancer therapies like trastuzumab and bevacizumab are associated with varying rates of cardiotoxicity.
Design
Review of cardiotoxic chemotherapy agents
Authors
Discussion
Loading...
Member takes
Implication
Alerts clinicians to chemotherapy cardiotoxicity risks; leaves open optimal monitoring and prevention strategies.
Structured PICO
P
Population
Patients receiving cardiotoxic chemotherapy (e.g., for breast, gastric, colorectal cancer, leukemia, GIST)
I
Intervention
Cardiotoxic chemotherapy agents (anastrozole, trastuzumab, bevacizumab, imatinib, dasatinib)
Review of cardiotoxic risks associated with various chemotherapy agents.
Cite This Study
Witteles et al. (2015) studied this question. Targeted cancer therapies, including trastuzumab and bevacizumab, are associated with varying frequencies of cardiotoxic adverse events ranging from rare to very common.